Marker Therapeutics (MRKR) Shares Dip 3.3% as T‑Cell Immuno‑Oncology Eyes Clinical Milestones
Marker Therapeutics (MRKR) slides 3.3% as investors eye upcoming T‑cell trial milestones and potential partnership wins in a volatile biotech market.
- MARKER THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read